Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Takeaways: The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, pa...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for TEVIMBRA + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metas...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Ontario’s reimbursement of BRAFTOVI is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
Takeaways Ontario’s first dedicated AI safety division could make PSHSA a more important player in workplace compliance by turning its expertise into scalable digital tools. The ...
Takeaways Novartis is using this initiative to deepen its positioning as a “health equity partner” to government and community groups in Canada, with a fresher focus on women and gender‑diverse ...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
The pharmaceutical industry has long occupied a complex position in public perception, celebrated for life saving innovation yet frequently criticized for pricing practices, transparency concerns, and...
